SYRS vs. SGMT, PDSB, DMAC, FGEN, RPTX, AMLX, ACET, NVCT, RGLS, and INCR
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Sagimet Biosciences (SGMT), PDS Biotechnology (PDSB), DiaMedica Therapeutics (DMAC), FibroGen (FGEN), Repare Therapeutics (RPTX), Amylyx Pharmaceuticals (AMLX), Adicet Bio (ACET), Nuvectis Pharma (NVCT), Regulus Therapeutics (RGLS), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry.
Syros Pharmaceuticals (NASDAQ:SYRS) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Sagimet Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals.
Sagimet Biosciences has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -1,656.34%. Sagimet Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
Syros Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 176.68%. Sagimet Biosciences has a consensus target price of $39.60, suggesting a potential upside of 833.96%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Syros Pharmaceuticals.
Syros Pharmaceuticals received 348 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 63.94% of users gave Syros Pharmaceuticals an outperform vote.
In the previous week, Syros Pharmaceuticals had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Syros Pharmaceuticals and 3 mentions for Sagimet Biosciences. Syros Pharmaceuticals' average media sentiment score of 0.80 beat Sagimet Biosciences' score of 0.79 indicating that Syros Pharmaceuticals is being referred to more favorably in the media.
91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Sagimet Biosciences beats Syros Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
